S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
S&P 500   3,325.00 (+0.13%)
DOW   29,174.04 (-0.08%)
QQQ   224.37 (+0.49%)
AAPL   318.56 (+0.63%)
FB   221.88 (+0.20%)
MSFT   166.18 (-0.19%)
GOOGL   1,488.91 (+0.45%)
AMZN   1,889.46 (-0.13%)
CGC   24.39 (+0.99%)
NVDA   251.96 (+1.62%)
BABA   223.16 (+0.40%)
MU   59.54 (+0.97%)
GE   11.41 (-2.23%)
TSLA   589.34 (+7.70%)
AMD   51.51 (+0.90%)
ACB   2.04 (+1.49%)
F   9.19 (-0.22%)
BAC   34.24 (-0.06%)
DIS   143.92 (+0.24%)
GILD   63.08 (+0.72%)
Log in

NASDAQ:KYTH - Kythera Biopharmaceuticals Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.10
0.00 (0.00 %)
(As of 12/9/2019)
Add
Today's Range
$0.10
Now: $0.10
$0.10
50-Day Range
$0.09
MA: $0.09
$0.09
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
KYTHERA Biopharmaceuticals, Inc (KYTHERA) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of prescription products for the aesthetic medicine market. The Company's initial focus is on the facial aesthetics market. The Company's product candidate is ATX101, an injectable drug in late-stage clinical development for the treatment of submental fullness associated with submental fat, which commonly presents as an undesirable double chin. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryBiotechnology
SectorN/A
Current SymbolNASDAQ:KYTH
CUSIP50157010
WebN/A
Phone+1-818-5874500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive KYTH News and Ratings via Email

Sign-up to receive the latest news and ratings for KYTH and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Kythera Biopharmaceuticals (NASDAQ:KYTH) Frequently Asked Questions

What is Kythera Biopharmaceuticals' stock symbol?

Kythera Biopharmaceuticals trades on the NASDAQ under the ticker symbol "KYTH."

How were Kythera Biopharmaceuticals' earnings last quarter?

Kythera Biopharmaceuticals Inc (NASDAQ:KYTH) posted its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.10) by $0.34. The biopharmaceutical company had revenue of $288 million for the quarter. View Kythera Biopharmaceuticals' Earnings History.

Has Kythera Biopharmaceuticals been receiving favorable news coverage?

Headlines about KYTH stock have trended somewhat negative recently, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kythera Biopharmaceuticals earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned media headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Kythera Biopharmaceuticals.

Who are some of Kythera Biopharmaceuticals' key competitors?

What other stocks do shareholders of Kythera Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kythera Biopharmaceuticals investors own include Gilead Sciences (GILD), Raptor Pharmaceutical (RPTP), Bausch Health Companies (BHC), Altaba (AABA), Celgene (CELG), Intercept Pharmaceuticals (ICPT), Incyte (INCY), Shire-Nps Pharmaceuticals (NPSP), Opko Health (OPK) and Puma Biotechnology (PBYI).

What is Kythera Biopharmaceuticals' stock price today?

One share of KYTH stock can currently be purchased for approximately $0.10.

How can I contact Kythera Biopharmaceuticals?

Kythera Biopharmaceuticals' mailing address is 27200 Agoura Rd Ste 200, AGOURA HILLS, CA 91301-5127, United States. The biopharmaceutical company can be reached via phone at +1-818-5874500.


MarketBeat Community Rating for Kythera Biopharmaceuticals (NASDAQ KYTH)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  105 (Vote Outperform)
Underperform Votes:  73 (Vote Underperform)
Total Votes:  178
MarketBeat's community ratings are surveys of what our community members think about Kythera Biopharmaceuticals and other stocks. Vote "Outperform" if you believe KYTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KYTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel